[Intratumoral injection of OK-432 in conjunction with fibrinogen greatly enhances antitumor effect on colorectal carcinomas].
We found that antitumor effect of OK-432, a lyophylized preparation of an attenuated strain of streptococcus pyogenes, on colorectal carcinoma was greatly augmented when it was injected intratumorally in conjunction with fibrinogen. Twenty cases of colorectal cancer received intratumoral injection of 5 KE of OK-432 mixed with 80mg of fibrinogen including factor-XIII and 1ml of aprotinin at the time of endoscopic examination. Changes in the shape of the tumors were observed endoscopically within a few days after injection, and in most cases, decrease in the height of tumor margin was noted. Histopathological findings on surgically resected specimens revealed that the fine meshwork of fibrin was formed at the injected site soon after the injection, and a marked infiltration of inflammatory cells including neutrophils, plasma cells, macrophages, eosinophils and lymphocytes. Such granulomatous changes developed over 7 days after injection, and the degradation of tumors were observed. By 14 days after the injection, tumor tissues were largely replaced with granulomas, and shrinkage of tissues were observed. These findings indicated that fibrinogen including factor-XIII and aprotinin has a potential ability to augment the immunoreaction induced by biological response modifiers, and intratumoral injection of OK-432 in conjunction with fibrinogen solution was superior to intratumoral injection of OK-432 alone as the local immunotherapy of colorectal cancer.
Monden
T
T
Second Department of Surgery, Osaka University Medical School, Japan.
Morimoto
H
H
Murotani
M
M
Yagyu
T
T
Nagaoka
H
H
Shimano
T
T
Mori
T
T
D007611:Aprotinin / Q000008:administration & dosage / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000473:pathology / Q000628:therapy*; D005176:Factor XIII / Q000008:administration & dosage / Q000627:therapeutic use; D005340:Fibrinogen / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000627:therapeutic use; D015552:Injections, Intralesional; D010844:Picibanil / Q000008:administration & dosage* / Q000627:therapeutic use; D012074:Remission Induction
D007155:Immunologic Factors; D010844:Picibanil; D005340:Fibrinogen; D005176:Factor XIII; D007611:Aprotinin